Senem Alanyali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Senem Alanyali has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Ayfer Haydaroğlu
Ege Üniversitesi Tıp Fakültesi Radyasyon Onkolojisi Anabilim Dalı, İzmir
3 shared publications - Necmettin Özdemi̇r
Ege Üniversitesi Tıp Fakültesi, Patoloji Anabilim Dalı, İzmir
3 shared publications - Osman Zekioglu
Ege Üniversitesi Tıp Fakültesi, Patoloji Anabilim Dalı, İzmir
3 shared publications - Zeynep Özsaran
Ege Üniversitesi Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Dalı, İzmir
3 shared publications - Ahmet Aydın ÖZSARAN
Ege Üniversitesi Tıp Fakültesi, Jinekolojik Onkoloji Bilim Dalı, İzmir
2 shared publications - Erdem Göker
Department of Medical Oncology, Faculty of Medicine, Ege University, 35100 Izmir, Turkey
2 shared publications
Latest Publications
- Open Access
- 4 August 2025
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 21 (4) , 379-383
Safe Delivery of Radiotherapy for Breast Cancer Patient With Left Ventricular Assist Device: Case Report and Review of the Literature
The increasing use of cardiac artificial devices, such as cardiac implantable electronic devices (CIED) and left ventricular assist devices (LVAD), results in longer life expectancy and thus may eventually coincide with a risk of cancer diagnosis and requirement for radiotherapy. Safe irradiation dose limits are better studied and reported for CIEDs, but data on LVAD irradiation are scarce. We present a case of a patient diagnosed with breast cancer who developed heart failure and was given an LVAD, received appropriate oncological care including chemotherapy, surgery, and, after careful multidisciplinary review, radiotherapy. The patient's right-sided initial stage II (T1N1) disease necessitated radiation treatment to the chest wall and regional lymphatic nodal areas. Meticulous radiotherapy planning and treatment delivery were performed, and daily LVAD performance checks were done. Maximum and mean doses received by the LVAD system were 767 cGy and 227 cGy, respectively, for the whole treatment period (5000 cGy/25 fractions). During radiotherapy and after 41 months of follow-up, no VLAD malfunction was observed. As this case shows, having an LVAD does not appear to be a contraindication for radiotherapy delivery. Possible risks and consequences should be evaluated in a multidisciplinary setting.
- 4 August 2025
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 21 (4) , 379-383
Open AccessSafe Delivery of Radiotherapy for Breast Cancer Patient With Left Ventricular Assist Device: Case Report and Review of the Literature
The increasing use of cardiac artificial devices, such as cardiac implantable electronic devices (CIED) and left ventricular assist devices (LVAD), results in longer life expectancy and thus may eventually coincide with a risk of cancer diagnosis and requirement for radiotherapy. Safe irradiation dose limits are better studied and reported for CIEDs, but data on LVAD irradiation are scarce. We present a case of a patient diagnosed with breast cancer who developed heart failure and was given an LVAD, received appropriate oncological care including chemotherapy, surgery, and, after careful multidisciplinary review, radiotherapy. The patient's right-sided initial stage II (T1N1) disease necessitated radiation treatment to the chest wall and regional lymphatic nodal areas. Meticulous radiotherapy planning and treatment delivery were performed, and daily LVAD performance checks were done. Maximum and mean doses received by the LVAD system were 767 cGy and 227 cGy, respectively, for the whole treatment period (5000 cGy/25 fractions). During radiotherapy and after 41 months of follow-up, no VLAD malfunction was observed. As this case shows, having an LVAD does not appear to be a contraindication for radiotherapy delivery. Possible risks and consequences should be evaluated in a multidisciplinary setting.
- Open Access
- 10 November 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (45) , e35280
Investigating the levels of depression, anxiety, sexual disorders, and other influencing factors in breast cancer patients: Turkish radiation oncology integrative group study (TROD 12-05)
The fear of death associated with cancer and the side effects of its treatments can have a detrimental psychological impact on breast cancer patients. Early detection and support services play a crucial role in alleviating the expected symptoms of depression, anxiety, and sexual dysfunction. The objective of our study is to assess the levels of depression, anxiety, and sexual dysfunction in breast cancer patients, as well as identify the factors that influence these conditions. The study involved 329 voluntarily participating breast cancer patients who had undergone surgery and were in the follow-up stage. Data were collected from 8 different centers after obtaining ethical approval. The assessment utilized tools such as the Sociodemographic Information Form, Beck Depression and Anxiety Scale, and Arizona Sexual Experiences Scale. Data analysis was performed using SPSS 20. The study included 329 breast cancer patients in the follow-up stage post-surgery. Their average age was 52.7 years (range: 27–83). Results indicated that 33.1% experienced moderate to severe depression, 18.2% reported severe anxiety, and 82.7% scored above 11 on the sexual scale. Factors linked to higher scores were mastectomy, surgical dissatisfaction, insufficient information on sexual side effects, and comorbidities like smoking and diabetes. The study emphasizes the importance of closely monitoring anxiety, depression levels, and sexual side effects in breast cancer treatment. It underscores the need to focus not only on reducing mortality rates but also on supporting patients’ psychological and sexual well-being, ultimately improving their overall quality of life.
- 10 November 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (45) , e35280
Open AccessInvestigating the levels of depression, anxiety, sexual disorders, and other influencing factors in breast cancer patients: Turkish radiation oncology integrative group study (TROD 12-05)
The fear of death associated with cancer and the side effects of its treatments can have a detrimental psychological impact on breast cancer patients. Early detection and support services play a crucial role in alleviating the expected symptoms of depression, anxiety, and sexual dysfunction. The objective of our study is to assess the levels of depression, anxiety, and sexual dysfunction in breast cancer patients, as well as identify the factors that influence these conditions. The study involved 329 voluntarily participating breast cancer patients who had undergone surgery and were in the follow-up stage. Data were collected from 8 different centers after obtaining ethical approval. The assessment utilized tools such as the Sociodemographic Information Form, Beck Depression and Anxiety Scale, and Arizona Sexual Experiences Scale. Data analysis was performed using SPSS 20. The study included 329 breast cancer patients in the follow-up stage post-surgery. Their average age was 52.7 years (range: 27–83). Results indicated that 33.1% experienced moderate to severe depression, 18.2% reported severe anxiety, and 82.7% scored above 11 on the sexual scale. Factors linked to higher scores were mastectomy, surgical dissatisfaction, insufficient information on sexual side effects, and comorbidities like smoking and diabetes. The study emphasizes the importance of closely monitoring anxiety, depression levels, and sexual side effects in breast cancer treatment. It underscores the need to focus not only on reducing mortality rates but also on supporting patients’ psychological and sexual well-being, ultimately improving their overall quality of life.
- Open Access
- 31 December 2019
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 58, 33-38
Epidemiologic fetaures and survival outcomes of carcinoma of the corpus uteri
Amaç: Ege Üniversitesi Hastanesinde 1992-2017 arası kanser tanı ve tedavisi yapılan 3379 korpus uteri kanserinin epidemiyolojik ve sağ kalım özelliklerini analiz etmek ve sonuçları literatürle karşılaştırmaktır. Gereç ve Yöntem: Ege Üniversitesi Kanserle Savaş Araştırma ve Uygulama Merkezi tarafından toplanan korpus uteri kanseri verileri CANREG özel bilgisayar programına kayıt edilmiş, DSÖ ve SEER sistemleri temelinde gruplanarak analizler yapılmıştır. İstatistik analizlerde Ki-kare, General Linear Model, Kaplan Meier sağ kalım analizleri uygulanmıştır. Kaplan Meier Sağ kalım analizinde Log Rank (Mantel-Cox), Breslow (Generalized Wilcoxon) ve Tarone-Ware istatistikleri kullanılmıştır. İstatistik analizlerde p
- 31 December 2019
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 58, 33-38
Open AccessEpidemiologic fetaures and survival outcomes of carcinoma of the corpus uteri
Amaç: Ege Üniversitesi Hastanesinde 1992-2017 arası kanser tanı ve tedavisi yapılan 3379 korpus uteri kanserinin epidemiyolojik ve sağ kalım özelliklerini analiz etmek ve sonuçları literatürle karşılaştırmaktır. Gereç ve Yöntem: Ege Üniversitesi Kanserle Savaş Araştırma ve Uygulama Merkezi tarafından toplanan korpus uteri kanseri verileri CANREG özel bilgisayar programına kayıt edilmiş, DSÖ ve SEER sistemleri temelinde gruplanarak analizler yapılmıştır. İstatistik analizlerde Ki-kare, General Linear Model, Kaplan Meier sağ kalım analizleri uygulanmıştır. Kaplan Meier Sağ kalım analizinde Log Rank (Mantel-Cox), Breslow (Generalized Wilcoxon) ve Tarone-Ware istatistikleri kullanılmıştır. İstatistik analizlerde p
- Open Access
- 31 December 2019
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 58, 39-43
Serviks uteri kanserlerinin epidemiyoloji ve sağ kalım özellikleri
Tr en Amaç: Ege Üniversitesi Hastanesinde 1992-2017 arası kanser tanı ve tedavisi yapılan 2647 serviks uteri kanserinin epidemiyolojik ve sağ kalım özelliklerini analiz etmek ve sonuçları literatürle karşılaştırmaktır. Gereç ve Yöntem: Ege Üniversitesi Kanserle Savaş Araştırma ve Uygulama Merkezi tarafından toplanan serviks uteri kanseri verileri CANREG özel bilgisayar programına kaydedilmiş, DSÖ ve SEER sistemleri temelinde gruplanarak analizler yapılmıştır. İstatistik analizlerde Ki-kare, General Linear Model, Kaplan Meier sağ kalım analizleri uygulanmıştır. Kaplan Meier Sağ kalım analizinde LogRank (Mantel-Cox), Breslow (Generalized Wilcoxon) ve Tarone-Ware istatistikleri kullanılmıştır. İstatistik analizlerde p<0.05 istatistiksel olarak anlamlı kabul edilmiştir. Bulgular: Serviks uteri kanserinin jinekolojik kanserler arasında görülme oranı %31,8 olarak saptanmıştır. En sık görüldüğü yaş grubu 40-49’dur. En sık görülen histolojik alt tip, yassı hücreli kanser olup, onu adenokanserler takip etmiştir. Hastalar en sık lokal ileri evrede tanı almaktadır (%47,2). Ortalama sağ kalım süresi 120 ay olarak saptanmıştır. Beş yılık genel sağ kalım oranı %70,4, 10 yıllık genel sağ kalım oranı ise %59,4 olarak bulunmuştur. Sonuç: Serviks uteri kanseri, jinekolojik kanserler arasında önemli bir yer tutmaktadır. Hastanemizin 2beş yıllık kayıtları değerlendirildiğinde, demografik verilerin ve histopatolojik bulguların literatür ile uyumlu olduğu, sağ kalım sürelerinin ise gelişmiş ülkeler ile benzer hatta ileri evre olgularda daha iyi olduğu görülmektedir. Aim: Aim of this study is to evaluate epidemiologic features and survival outcomes of 2647 patients treated with the diagnosis of cervical cancer (CC) in Ege University Hospital (EUH) between 1992-2017 and compare them with the literature. Materials and Methods: Data recorded to CANREG-4 program in EUH between 1992-2017 by EU Fight Against Cancer Research and Application Center (EUKAM) were grouped according to WHO and SEER systems. For statistical analysis, Chi-square method and general linear modeling and Kaplan-Meier analysis were performed. In Kaplan-Meier analysis, Log Rank (Mantel-Cox), Breslow (Generalized Wilcxon) and Tarone-Ware methods were used. p<0.05 was accepted as significant. Results: Cervical cancer consisted 31.8% of gynecologic malignancies. It was mostly seen at the ages between 40-49. Most common histologic subtype was squamous cell cancer; it was followed by adenocarcinoma of the cervix. Patients were mostly diagnosed at the local advanced stage (47.2%). Median survival was 120 months. 5 year overall survival rate was 70.4% and 10 year overall survival rate was 59.4%. Conclusion: Cervical cancer is an important type of gynecologic malignancies. When 25 years data of our hospital was evaluated, demographic and histolopathologic data were found similar with the literature, additionally survival was found similar and even better in metastatic disease according to developed countries.
- 31 December 2019
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 58, 39-43
Open AccessServiks uteri kanserlerinin epidemiyoloji ve sağ kalım özellikleri
Tr en Amaç: Ege Üniversitesi Hastanesinde 1992-2017 arası kanser tanı ve tedavisi yapılan 2647 serviks uteri kanserinin epidemiyolojik ve sağ kalım özelliklerini analiz etmek ve sonuçları literatürle karşılaştırmaktır. Gereç ve Yöntem: Ege Üniversitesi Kanserle Savaş Araştırma ve Uygulama Merkezi tarafından toplanan serviks uteri kanseri verileri CANREG özel bilgisayar programına kaydedilmiş, DSÖ ve SEER sistemleri temelinde gruplanarak analizler yapılmıştır. İstatistik analizlerde Ki-kare, General Linear Model, Kaplan Meier sağ kalım analizleri uygulanmıştır. Kaplan Meier Sağ kalım analizinde LogRank (Mantel-Cox), Breslow (Generalized Wilcoxon) ve Tarone-Ware istatistikleri kullanılmıştır. İstatistik analizlerde p<0.05 istatistiksel olarak anlamlı kabul edilmiştir. Bulgular: Serviks uteri kanserinin jinekolojik kanserler arasında görülme oranı %31,8 olarak saptanmıştır. En sık görüldüğü yaş grubu 40-49’dur. En sık görülen histolojik alt tip, yassı hücreli kanser olup, onu adenokanserler takip etmiştir. Hastalar en sık lokal ileri evrede tanı almaktadır (%47,2). Ortalama sağ kalım süresi 120 ay olarak saptanmıştır. Beş yılık genel sağ kalım oranı %70,4, 10 yıllık genel sağ kalım oranı ise %59,4 olarak bulunmuştur. Sonuç: Serviks uteri kanseri, jinekolojik kanserler arasında önemli bir yer tutmaktadır. Hastanemizin 2beş yıllık kayıtları değerlendirildiğinde, demografik verilerin ve histopatolojik bulguların literatür ile uyumlu olduğu, sağ kalım sürelerinin ise gelişmiş ülkeler ile benzer hatta ileri evre olgularda daha iyi olduğu görülmektedir. Aim: Aim of this study is to evaluate epidemiologic features and survival outcomes of 2647 patients treated with the diagnosis of cervical cancer (CC) in Ege University Hospital (EUH) between 1992-2017 and compare them with the literature. Materials and Methods: Data recorded to CANREG-4 program in EUH between 1992-2017 by EU Fight Against Cancer Research and Application Center (EUKAM) were grouped according to WHO and SEER systems. For statistical analysis, Chi-square method and general linear modeling and Kaplan-Meier analysis were performed. In Kaplan-Meier analysis, Log Rank (Mantel-Cox), Breslow (Generalized Wilcxon) and Tarone-Ware methods were used. p<0.05 was accepted as significant. Results: Cervical cancer consisted 31.8% of gynecologic malignancies. It was mostly seen at the ages between 40-49. Most common histologic subtype was squamous cell cancer; it was followed by adenocarcinoma of the cervix. Patients were mostly diagnosed at the local advanced stage (47.2%). Median survival was 120 months. 5 year overall survival rate was 70.4% and 10 year overall survival rate was 59.4%. Conclusion: Cervical cancer is an important type of gynecologic malignancies. When 25 years data of our hospital was evaluated, demographic and histolopathologic data were found similar with the literature, additionally survival was found similar and even better in metastatic disease according to developed countries.
- Open Access
- 31 December 2019
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 58, 50-57
Ege Üniversitesi Hastanesi veri tabanında meme kanseri hastalarının epidemiyolojisi ve genel sağ kalım özellikleri
Amaç: Ege Üniversitesi Hastanesinde 1992-2017 arası kanser tanı ve tedavisi yapılan 13079 meme kanser tanılı hastanın genel özellikleri, tedavi modaliteleri ve sağ kalım sürelerinin tanımlanması amaçlanmıştır. Gereç ve Yöntem: Ege Üniversitesi Kanserle Savaş Araştırma ve Uygulama Merkezi tarafından toplanan meme kanseri verileri CANREG özel bilgisayar programına kayıt edilmiş, DSÖ ve SEER sistemleri temelinde gruplanarak analizler yapılmıştır. İstatistik analizlerde Ki-kare, General Linear Model, Kaplan Meier sağ kalım analizleri uygulanmıştır. Kaplan Meier Sağ kalım analizinde Log Rank (Mantel-Cox), Breslow (Generalized Wilcoxon) ve Tarone-Ware istatistikleri kullanılmıştır. İstatistik analizlerde p
- 31 December 2019
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 58, 50-57
Open AccessEge Üniversitesi Hastanesi veri tabanında meme kanseri hastalarının epidemiyolojisi ve genel sağ kalım özellikleri
Amaç: Ege Üniversitesi Hastanesinde 1992-2017 arası kanser tanı ve tedavisi yapılan 13079 meme kanser tanılı hastanın genel özellikleri, tedavi modaliteleri ve sağ kalım sürelerinin tanımlanması amaçlanmıştır. Gereç ve Yöntem: Ege Üniversitesi Kanserle Savaş Araştırma ve Uygulama Merkezi tarafından toplanan meme kanseri verileri CANREG özel bilgisayar programına kayıt edilmiş, DSÖ ve SEER sistemleri temelinde gruplanarak analizler yapılmıştır. İstatistik analizlerde Ki-kare, General Linear Model, Kaplan Meier sağ kalım analizleri uygulanmıştır. Kaplan Meier Sağ kalım analizinde Log Rank (Mantel-Cox), Breslow (Generalized Wilcoxon) ve Tarone-Ware istatistikleri kullanılmıştır. İstatistik analizlerde p
- Open Access
- 1 January 2017
- Published by LookUs Bilisim A.S. in Turkish Journal of Oncology
Expression of Cyclin D1 and its relationship to hormone receptors and survival in breast cancer
- 1 January 2017
- Published by LookUs Bilisim A.S. in Turkish Journal of Oncology
Open AccessExpression of Cyclin D1 and its relationship to hormone receptors and survival in breast cancer
- 14 April 2016
- Published by SAGE Publications in Tumori Journal
- Vol. 102 (3) , 311-315
Treatment Results and Prognostic Factors of Patients with Vulvar Cancer Treated with Postoperative or Definitive Radiotherapy
Purpose: Vulvar cancer is a relatively uncommon type of gynecologic cancer. The aim of this study is to analyze the treatment results and prognostic factors of vulvar cancer. Methods: Forty-four vulvar cancer patients treated between 2000 and 2011 at the Department of Radiation Oncology, Ege University Faculty of Medicine, were retrospectively reviewed. External radiotherapy (RT) was applied with 6-18 MV linear accelerators with 1.8 Gy daily fractions with a median total dose of 50.4 Gy (45-59.4 Gy) for postoperative cases and 64.8 Gy (range 54-66 Gy) for definitive cases. Statistical analyses were performed with SPSS 13.0. Results: Among 44 patients with a median age of 68 years (range 28-86), 14 (31.8%) were treated with curative and 30 (68.2%) were treated with postoperative RT or radiochemotherapy (RCT). According to International Federation of Gynecology and Obstetrics staging, 11 (25%) had stage IB, 10 (22.7%) had stage II, 6 (13.6%) had stage IIIA, 5 (11.4%) had stage IIIB, and 12 (27.3%) had stage IVA disease. Within a median of 24 months (range 6-135) of follow-up, 11 (27.3%) patients had local recurrence, 8 had regional recurrence, 2 had both local and regional recurrence, and 6 had distant metastases. Five-year locoregional, disease-free, and overall survival rates were 45%, 40%, and 54%, respectively. Older age, poor tumor differentiation, positive surgical margin, and lymphovascular space invasion were found to be important prognostic factors for disease-related outcomes. Conclusions: Prognosis of vulvar cancer remains poor even with a multidisciplinary approach. Molecular prognostic factors need to be defined for individualized treatment options to achieve better treatment results.
- 14 April 2016
- Published by SAGE Publications in Tumori Journal
- Vol. 102 (3) , 311-315
Treatment Results and Prognostic Factors of Patients with Vulvar Cancer Treated with Postoperative or Definitive Radiotherapy
Purpose: Vulvar cancer is a relatively uncommon type of gynecologic cancer. The aim of this study is to analyze the treatment results and prognostic factors of vulvar cancer. Methods: Forty-four vulvar cancer patients treated between 2000 and 2011 at the Department of Radiation Oncology, Ege University Faculty of Medicine, were retrospectively reviewed. External radiotherapy (RT) was applied with 6-18 MV linear accelerators with 1.8 Gy daily fractions with a median total dose of 50.4 Gy (45-59.4 Gy) for postoperative cases and 64.8 Gy (range 54-66 Gy) for definitive cases. Statistical analyses were performed with SPSS 13.0. Results: Among 44 patients with a median age of 68 years (range 28-86), 14 (31.8%) were treated with curative and 30 (68.2%) were treated with postoperative RT or radiochemotherapy (RCT). According to International Federation of Gynecology and Obstetrics staging, 11 (25%) had stage IB, 10 (22.7%) had stage II, 6 (13.6%) had stage IIIA, 5 (11.4%) had stage IIIB, and 12 (27.3%) had stage IVA disease. Within a median of 24 months (range 6-135) of follow-up, 11 (27.3%) patients had local recurrence, 8 had regional recurrence, 2 had both local and regional recurrence, and 6 had distant metastases. Five-year locoregional, disease-free, and overall survival rates were 45%, 40%, and 54%, respectively. Older age, poor tumor differentiation, positive surgical margin, and lymphovascular space invasion were found to be important prognostic factors for disease-related outcomes. Conclusions: Prognosis of vulvar cancer remains poor even with a multidisciplinary approach. Molecular prognostic factors need to be defined for individualized treatment options to achieve better treatment results.